-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Emerging Companies
Crowdfunding Goes Viral
Is crowdfunding a viable source of capital for biotech companies? μBiome thinks so; they are a startup biotech company that raised $351,193. They asked for $100,000. That’s right; over three times their goal. “[Crowdfunding for biotech] is an idea whose time has come,” says μBiome’s CEO Jessica Richman. “The fact that we did it is proof of that. We’re the first ones but there will be lots of others.” Is there a way that crowdfunding could help Read More >
Small Biotech Companies and China: 5 Keys to Success
Big pharmaceutical countries aren’t the only ones investing in China. Emerging and mid-sized biotech companies are also exploring ways to enter China’s lucrative market and maximize their investment in the country. With limited resources, how can smaller companies operate efficiently and give Chinese patients access to their innovative products? A panel of experts explored these questions at the 2013 BIO CEO & Investor Conference. Jimmy Zhang from Merck moderated a panel including: Friedhelm Blobel, PhD, President, CEO, Read More >
Biotech Hall of Fame: Interview with Biotech’s First Investment Banker
Earlier this week, I had the opportunity to discuss biotech’s storied history with Fred Frank, one of the industry’s greatest luminaries, on what we can learn from the past to help shape the future. Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life Read More >
Small Companies, Big Returns
The broader biotech indices are up more than 30 percent this year and have reached levels not seen since the peak of March 2000. Larger biotechs account for much of the index returns, as we have described previously, and have helped the sector outperform the S&P 500 by two fold. But how have smaller biotech companies been performing? As of Nov 30, 27 companies that started the year under $1 billion in market capitalization have Read More >
2012 BIO Investor Forum: Looking Ahead to Investment Opportunities
The biggest biotech news out of Washington in recent months was the Jumpstart Our Business Startups (JOBS) Act, which passed Congress overwhelmingly and was signed into law by President Obama in April. For those not familiar, the JOBS Act creates a new category of issuers, called “emerging growth companies” (EGCs), which is defined as newly public companies with than $1 billion in annual revenues and a public float below $700 million. EGCs are given a Read More >
